ConductScience.org, home

Paper39677358

Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.

Friedberg JW and 17 others. EClinicalMedicine, 2024. Cited by 8 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. Papers, record 39677358. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39677358

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
PubMed
Journal
EClinicalMedicine
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.88, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Friedberg JWJonathan W
2Brady MTMichael T
3Strawderman MMyla
4Kahl BSBrad S
5Lossos ISIzidore S
6Cohen JBJonathon B
7Reagan PMPatrick M
8Casulo CCarla
9Averill BLBarbara L
10Baran AAndrea
11Sutamtewagul GGrerk
12Barr PMPaul M
13Leonard JPJohn P
14Ashton JMJohn M
15Strang JGJohn G
16Vega FFrancisco
17Peterson DRDerick R
18Nastoupil LJLoretta J

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA214890NCI NIH HHSUnited StatesR01CA214890PubMed and NIHNIH RePORTER
U01 CA195568NCI NIH HHSUnited StatesU01CA195568PubMed and NIHNIH RePORTER
UL1 TR002001NCATS NIH HHSUnited StatesUL1TR002001PubMed and NIHNIH RePORTER

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03078855A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's LymphomaDerived from the trialYes

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19,060,552
Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.
J Clin Oncol1997https://conductscience.org/library/papers/9060552PubMed
233,836,47925-Hydroxy vitamin D deficiency predicts inferior prognosis in Hodgkin lymphoma.Leuk Res2021https://conductscience.org/library/papers/33836479PubMed
338,662,827Vitamin D regulates microbiome-dependent cancer immunity.Science2024https://conductscience.org/library/papers/38662827PubMed
425,694,350A dose-response study of vitamin D3 supplementation in healthy Chinese: a 5-arm randomized, placebo-controlled trial.Eur J Nutr2016https://conductscience.org/library/papers/25694350PubMed
52,003,990Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma.Br J Cancer1991https://conductscience.org/library/papers/2003990PubMed
623,175,624ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).Ann Oncol2013https://conductscience.org/library/papers/23175624PubMed
738,194,625Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.J Clin Oncol2024https://conductscience.org/library/papers/38194625PubMed
830,897,038AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.J Clin Oncol2019https://conductscience.org/library/papers/30897038PubMed
98,398,690The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.Br J Cancer1993https://conductscience.org/library/papers/8398690PubMed
1033,215,701Gene expression profile unveils diverse biological effect of serum vitamin D in Hodgkin's and diffuse large B-cell lymphoma.Hematol Oncol2021https://conductscience.org/library/papers/33215701PubMed
1128,841,207Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.Blood Cancer J2017https://conductscience.org/library/papers/28841207PubMed
1225,135,997Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.J Clin Oncol2014https://conductscience.org/library/papers/25135997PubMed
1325,154,829Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.J Clin Oncol2014https://conductscience.org/library/papers/25154829PubMed
1425,823,738Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.J Clin Oncol2015https://conductscience.org/library/papers/25823738PubMed
1538,701,347Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment.Blood Adv2024https://conductscience.org/library/papers/38701347PubMed
1624,256,378Vitamin D-binding protein and vitamin D status of black Americans and white Americans.N Engl J Med2013https://conductscience.org/library/papers/24256378PubMed
1725,113,753Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.J Clin Oncol2014https://conductscience.org/library/papers/25113753PubMed
1815,126,323Follicular lymphoma international prognostic index.Blood2004https://conductscience.org/library/papers/15126323PubMed
1927,959,647Vitamin D Deficiency - Is There Really a Pandemic?N Engl J Med2016https://conductscience.org/library/papers/27959647PubMed
2024,794,808Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma.Leuk Lymphoma2015https://conductscience.org/library/papers/24794808PubMed

See all 32 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42,394,759Vitamin D Supplementation and Treatment-Free Survival in Early-Stage CLL: A Real-World Validation Study.EJHaem2026https://conductscience.org/library/papers/42394759PubMed
42,163,640Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.Br J Haematol2026https://conductscience.org/library/papers/42163640PubMed
41,884,528Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity.Endocr Oncol2026https://conductscience.org/library/papers/41884528PubMed
41,424,936Current landscape of frontline and relapsed follicular lymphoma trials.Blood Neoplasia2025https://conductscience.org/library/papers/41424936PubMed
39,726,364Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.Eur J Haematol2025https://conductscience.org/library/papers/39726364PubMed

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
RITUXIMABCHEMBL1201576Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201576ChEMBL
ERGOCALCIFEROLCHEMBL1536Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1536ChEMBL

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39677358

GET https://conductscience.org/api/papers/v1/39677358/references?page=2